Want to join the conversation?
Drug maker $REGN said Sarilumab, the company's IL-6 receptor antibody for treatment of rheumatoid arthritis is under review with the FDA. Dupilumab is being developed for a number of indications and $REGN is targeting completion of its BLA submission for moderate-to-severe atopic dermatitis in 3Q16.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.